Pricing Log in Create free account
Friday 6 November 2026 Export IBIO’s income statement to Excel — free account

iBio, Inc.

IBIO Healthcare Biotechnology

iBio, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $100,000.00, down 75.0% from fiscal 2025.

Revenue
+100.0%
EPS
+80.5%
Free cash flow
−35.3%

Quarter to June 2026, against a year earlier

0.75 0.02 +2.74%
Market cap
$44.4M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
4/9
Altman Z
2.80
Beneish M
33.49
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.10
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 3 — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 46.51%

Capital & Financial Ratios $m

Size
Market Cap 44.43
Revenue ttm 0.68
Net income ttm (33.04)
Free cash flow ttm (23.80)
Net debt Q (88.04)
Valuation
P/E 0.00
Forward P/E (1.95) (negative: loss-making)
Price / sales 115.62 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.91
Financial health
Current ratio Q 7.85 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 247.39
Growth
Revenue growth Q +100.00% (above 0%: growing)
Operating income growth Q −118.93% (below 0%: shrinking)
EPS, this year −23.21% (below 0%: weak)
EPS, next year A −49.64% (below 0%: weak)
Revenue, next year A −75.00% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −21.32% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −12.8×, against a ten-year median of 46.1×; over the ten years it ranged from −12.8× in 2026 to 338× in 2026.
P/S against its own 10 years 86.33%
10-year low 10-year high
P/B against its own 10 years 29.86%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 7 15 9 88
Receivables 0 1 0 1
Inventory — — — —
Other 18 — — —
26 16 10 92
2023 2024 2025 2026
Payables 2 0 2 4
ST’ Debt 13 0 1 —
Other 2 0 1 1
22 4 6 12

Compound Annual Growth %

10y 5y 3y
Sales (25.31%) (42.83%) (62.42%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 13.55% (4.62%) 77.29%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate −0.07 Actual −0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 −0.07 −0.11 Miss by 0.04
Q2 FY26 −0.08 −0.09 Miss by 0.01
Q3 FY26 −0.06 −0.07 Miss by 0.01
Q4 FY26 −0.07 −0.04 Beat by 0.03
Q1 FY27 −0.07 — Reports 11 November 2026

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 (0.11) (0.09) (0.07) (0.07) (0.32)
’25 (0.46) (0.48) (0.49) (0.36) (1.75)
’24 (4.80) (4.42) (0.85) (0.91) (6.50)
’23 (41.01) (68.40) (11.07) 14.33 (106.20)
’22 (20.00) (25.00) (30.00) (39.08) (115.60)
’21 (25.00) (20.00) (20.00) 0.00 (60.00)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 0 — — — 0
’25 — 0 — 0 0
’24 0 — — 0 0
’22 0 0 2 0 2
’21 0 1 1 0 2
’20 0 0 0 1 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (6) (5) (6) (6) (23)
’25 (4) (4) (3) (5) (15)
’24 (5) (5) (4) (5) (19)
’23 (14) (8) (4) (5) (30)
’22 (9) (11) (6) (12) (37)
’21 (7) (8) (7) (7) (30)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (6) (6) (6) (6) (24)
’25 (4) (4) (3) (5) (15)
’24 (5) (5) (3) (5) (18)
’23 (16) (11) (2) (5) (34)
’22 (13) (13) (8) (15) (49)
’21 (8) (9) (8) (10) (35)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 0 0 2 2 2 2 — 0 0 0 (14.1%) 0 0 0 (41.5%)
Gross margin, % 100.00 100.00 100.00 57.08 38.34 100.00 0.00 100.00 100.00 100.00 0.0 pt
EBT (16) (16) (18) (16) (23) (30) (29) (15) (18) (33) +8.3%
EBT margin, % (4,096.19) (3,627.93) (872.00) (1,003.91) (979.04) (1,566.51) 0.00 (6,863.56) (4,594.25) (33,044.00) (28,947.8) pt
Net income (16) (16) (18) (16) (23) (50) (65) (25) (18) (33) +8.3%
Per share, $
Per share, $ Revenue 22.13 20.85 53.25 13.04 6.06 4.32 0.00 0.06 0.04 0.00 (67.1%)
Earnings (800.00) (769.68) (464.43) (305.00) (60.00) (115.60) (106.20) (6.50) (1.75) (0.32) (58.1%)
Cash flow (739.49) (632.86) (368.73) (106.25) (76.83) (85.94) (49.73) (4.84) (1.46) (0.22) (59.4%)
Capex (89.49) (50.66) (26.12) (9.19) (13.19) (26.67) (5.13) 0.24 0.00 (0.01) (65.9%)
Free cash flow (828.99) (683.52) (394.85) (115.44) (90.02) (112.61) (54.86) (4.61) (1.46) (0.23) (59.8%)
Book value 500.84 758.87 64.83 450.69 277.45 145.57 25.13 5.57 1.42 0.82 (50.9%)
Shares, m 0 0 0 0 0 0 1 4 10 104 +162.1%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.0
P/S 88.10 20.87 6.57 85.11 124.60 27.63 — 3.80 12.77 269.79 71.0
P/B 3.89 0.57 5.40 2.46 2.72 0.89 — 0.36 0.54 2.12 2.1
EV/Sales 131.23 41.03 16.61 71.56 97.50 24.77 — (2.94) 1.39 141.38 58.1
EV/FCF (3.50) (1.25) (2.24) (8.00) (6.56) (1.03) — 0.31 (0.05) (3.94) (2.9)
Cash, $m
Cash, $m Operating cash flow (13) (13) (14) (13) (30) (37) (30) (19) (15) (23) +6.5%
Capex (2) (1) (1) (1) (5) (12) (3) 1 0 (1) (10.7%)
Free cash flow (15) (15) (15) (14) (35) (49) (34) (18) (15) (24) +5.5%
Balance, $m
Balance, $m Working capital 7 14 1 57 98 15 4 12 4 80 +32.1%
Net debt 17 9 20 (22) (64) (8) 6 (14) (8) (88) n/m
Shareholders’ equity 9 16 2 57 109 63 15 21 15 86 +28.6%
Returns, %
Returns, % ROA (33.38) (41.38) (48.47) (61.33) (19.46) (40.91) (92.47) (71.22) (70.79) (54.04) (20.7) pt
ROIC (34.19) (35.13) (43.05) (25.44) (43.88) (33.36) (84.34) (135.39) (163.11) 0.00 +34.2 pt
ROE (88.73) (130.51) (191.75) (129.55) (28.41) (58.58) (164.86) (135.71) (101.52) (65.70) +23.0 pt
People
People Employees 8 8 55 51 75 116 23 16 20 23 +12.5%
Revenue/emp, $m 0.05 0.06 0.04 0.03 0.03 0.02 0.00 0.01 0.02 0.00 (23.6%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Sep 2025 · fundamentals updated 26 Oct 2026

iBio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HYFT MindWalk Holdings Corp. $47.1M — (loss-making) — (loss-making) +19.37% (above 0%: growing) n/m +9.79% (above 0%: growing) 58.58% (159.86%) Compare
CNTB Connect Biopharma Holdings Limited Sponsored ADR $46.1M — (loss-making) — (loss-making) +296.56% (above 0%: growing) n/m −23.48% (below 0%: shrinking) 100.00% (635.98%) Compare
MREO Mereo BioPharma Group plc - Sponsored ADR $44.8M — (loss-making) — (loss-making) — n/m +21.02% (above 0%: growing) 0.00% 0.00% Compare
IBIO iBio, Inc. $44.4M — (loss-making) — (loss-making) +100.00% (above 0%: growing) n/m −35.33% (below 0%: shrinking) 100.00% 0.00%
CRBU Caribou Biosciences, Inc. $44.2M — (loss-making) — (loss-making) −26.89% (below 0%: shrinking) n/m +84.78% (above 0%: growing) 100.00% (1,720.10%) Compare
BMEA Biomea Fusion, Inc. $42.6M — (loss-making) — — n/m +47.80% (above 0%: growing) 0.00% 0.00% Compare
ATHE Alterity Therapeutics Limited - Sponsored ADR $42.4M — (loss-making) — — 0.00% −84.83% (below 0%: shrinking) 0.00% — Compare
GANX Gain Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +27.78% (above 0%: growing) n/m +8.22% (above 0%: growing) 0.00% 0.00% Compare
SER Serina Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $43.4M — — +27.78% — +9.00% 29.29% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 4 September 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 2.14m 2.31m 14.18
2025 1.51m 621.72k 6.25
2024 1.27m 1.18m 17.30

Ownership

Directors and executive officers, together 1.55%
Frazier Life Sciences Public Fund, L.P. and affiliates 9.99%
Sirenia Capital Management LP 9.99%
Affinity Asset Advisors, LLC 9.99%
Cormorant Global Healthcare Master Fund, LP 9.99%
Adage Capital Partners, L.P. 9.99%
SilverArc Capital Alpha Fund I, LP and affiliates 9.99%
Vestal Point Capital, LP 6.12%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

iBio, Inc. (IBIO) Latest News

13 Oct

Impact 4 · · GlobeNewswire

28 Aug

Impact 3 ·

1 Jul

Impact 4 ·

2 Jun

Impact 4 · · GlobeNewswire

12 May

Impact 3 · · GlobeNewswire

8 May

Impact 3 · · GlobeNewswire

24 Apr

Impact 4 · · Insider Monkey

8 Apr

Impact 4 · · MarketBeat
Impact 4 ·

20 Mar

Impact 4 · · MarketBeat

16 Mar

Impact 3 · · GlobeNewswire

9 Mar

Impact 4 · · GlobeNewswire

10 Feb

Impact 3 · · GlobeNewswire

2 Feb

Impact 4 · · Zacks

9 Jan

Impact 4 · · GlobeNewswire

20 Dec

Impact 3 · · Simply Wall St.Simply Wall St.

10 Dec

Impact 3 · · Associated Press Finance

9 Dec

Impact 3 · · Associated Press Finance

8 Dec

Impact 3 · · Associated Press Finance

12 Nov

Impact 3 · · ZacksZacksZacksZacksZacksGuruFocus.com
Impact 3 · · GlobeNewswire

30 Oct

Impact 4 · · GlobeNewswireMotley FoolClinical Trials ArenaMotley FoolReutersZacksMT NewswiresMT Newswires

21 Oct

Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

6 Sep

Impact 3 · · Simply Wall St.

5 Sep

Impact 3 · · GlobeNewswire

25 Aug

Impact 3 · · GlobeNewswire

19 Aug

Impact 3 · · GlobeNewswire

18 Aug

Impact 3 · · GlobeNewswire

24 Jun

Impact 4 · · GlobeNewswire
stockrow.com/IBIO · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com